

Antidepressant Treatment Selector

Charts revised November 2017. Full information available at www.hiv-druginteractions.org

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

		ATV/r	DRV/r	LPV/r	EFV	ETV	NVP	RPV	MVC	DTG	RAL	ABC	FTC	3TC	TDF	ZDV	E/C/F/TAF	E/C/F/TDF
SSRI	Citalopram	↑ ^a	↑	↑ ^a	↓	↓	↓	↔ ^a	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑
	Escitalopram	↑ ^a	↑	↑ ^a	↓	↓	↓	↔ ^a	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑
	Fluoxetine	↑	↑	↑	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑
	Fluvoxamine	↑	↑	↑	↔	↔	↑↑	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑
	Paroxetine	↑↓?	↓39%	↑↓?	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑↓?	↑↓?
SNRI	Sertraline	↓	↓49%	↓	↓39%	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↓7%	↔
	Duloxetine	↑↓	↑↓	↑↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑
TCA	Venlafaxine	↑	↑	↑	↓	↓	↓	↔	↓↓	↔	↔	↔	↔	↔	↔	↔	↑	↑
	Amitriptyline	↑ ^a	↑	↑ ^a	↔	↔	↔	↔ ^a	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑
	Clomipramine	↑ ^a	↑ ^a	↑ ^a	↓	↓	↓	↔ ^a	↔	↔	↔	↔	↔	↔	↔	↔	↑ ^a	↑ ^a
	Desipramine	↑ ^a	↑	↑5% ^a	↔	↔	↔	↔ ^a	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑
	Doxepin	↑	↑	↑	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑
	Imipramine	↑ ^a	↑ ^a	↑ ^a	↓	↓	↓	↔ ^a	↔	↔	↔	↔	↔	↔	↔	↔	↑ ^a	↑ ^a
	Nortriptyline	↑ ^a	↑	↑ ^a	↔	↔	↔	↔ ^a	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑
TeCA	Trimipramine	↑	↑	↑	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑
	Maprotiline	↑	↑	↑	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑
	Mianserin	↑	↑	↑	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑
Others	Mirtazapine	↑	↑	↑	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑
	Bupropion	↓	↓	↓57%	↓55%	↔	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑?	↑?
	Lamotrigine	↓32%	↓	↓50%	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
	Nefazodone	↑	↑	↑	↓↑↑	↓↑↑	↓↑↑	↑↑↑	↑↑↑	↔	↔	↔	↔	↔	↔	↔	↑	↑
	St John's wort	↓	↓	↓	↓	↓	↓	↓	↓	↓	↓	↓	↓	↓	↓	↓	↓	↓
	Trazodone	↑ ^a	↑	↑ ^a	↓	↓	↓	↔ ^a	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑

Colour Legend

- No clinically significant interaction expected.
- These drugs should not be coadministered.
- Potential interaction which may require a dosage adjustment or close monitoring.
- Potential interaction predicted to be of weak intensity. No *a priori* dosage adjustment is recommended.

Text Legend

- | | |
|--|---|
| ↑ Potential increased exposure of the antidepressant | ↑↑ Potential increased exposure of HIV drug |
| ↓ Potential decreased exposure of the antidepressant | ↓↓ Potential decreased exposure of HIV drug |
| ↔ No significant effect | |

Numbers refer to decreased AUC of the antidepressant as observed in drug-drug interaction studies.

SSRI selective serotonin reuptake inhibitors

SNRI serotonin and norepinephrine reuptake inhibitor

TCA tricyclic antidepressants

TeCA tetracyclic antidepressants

a ECG monitoring is recommended

b The US Prescribing Information recommends that coadministration should be avoided as there are insufficient data to make dosing recommendations. However, the European SPC suggests dolutegravir be dosed at 50 mg twice daily, but recommends alternative combinations to be used where possible in INSTI-resistant patients. (These charts reflect the more cautious option.)